Acinic cell carcinoma medical therapy

	Acinic cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acinic cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Surgery
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case studies
Case #1
Acinic cell carcinoma medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acinic cell carcinoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acinic cell carcinoma medical therapy
CDC on Acinic cell carcinoma medical therapy
Acinic cell carcinoma medical therapy in the news
Blogs on Acinic cell carcinoma medical therapy
Directions to Hospitals Treating Acinic cell carcinoma
Risk calculators and risk factors for Acinic cell carcinoma medical therapy

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD [2]

Overview

Low grade, low stage (I and II) and adequately resected acinic cell carcinoma are not considered for any further therapy, as their prognosis is excellent with surgery alone. Criteria for additional radiotherapy of acinic cell carcinoma does not differ with other salivary gland carcinomas. There is insufficient information regarding chemotherapy in acinic cell carcinoma. Observation of distant metastasis with a rate of 1 in 5 indicate the need for developing such regimen.

Medical Therapy

Low grade, low stage (I and II) and adequately resected acinic cell carcinoma are not considered for any further therapy, as their prognosis is excellent with surgery alone. additional medical therapies are:^[1]

Radiotherapy

Criteria for additional radiotherapy of acinic cell carcinoma does not differ with other salivary gland carcinomas and include:^[2]

Salvage surgery for recurrent disease
Advanced T-classification(T3/T4)
Positive surgical lymph margins
Pathologically positive cervical lymph node
Perineural invasion
High grade/Highly proliferative tumors.

Conversely Biron et al suggest that 'radiotherapy probably is not effective in acinic cell carcinoma.^[3]

Chemotherapy

There is insufficient information regarding chemotherapy in acinic cell carcinoma.^[4]
Some have suggested of positive effects of mTOR inhibitors due to acinic cell carcinoma, but no specific chemotherapy regimen have been currently approved.
Observation of distant metastasis with a rate of 1 in 5 indicate the need for developing such regimen.

References

↑ Vander Poorten, Vincent L. M.; Marchal, Francis; Nuyts, Sandra; Clement, Paul M. J. (2010). "Parotid carcinoma: Current diagnostic workup and treatment". Indian Journal of Surgical Oncology. 1 (2): 96–111. doi:10.1007/s13193-010-0022-x. ISSN 0975-7651.
↑ Patel, Neal R.; Sanghvi, Saurin; Khan, Mohemmed N.; Husain, Qasim; Baredes, Soly; Eloy, Jean Anderson (2013). "Demographic trends and disease‐specific survival in salivary acinic cell carcinoma: An analysis of 1129 cases". The Laryngoscope. 124 (1): 172–178. doi:10.1002/lary.24231. ISSN 0023-852X.
↑ Biron, Vincent L.; Lentsch, Eric J.; Gerry, Daniel R.; Bewley, Arnaud F. (2015). "Factors influencing survival in acinic cell carcinoma: A retrospective survival analysis of 2061 patients". Head & Neck. 37 (6): 870–877. doi:10.1002/hed.23686. ISSN 1043-3074.
↑ Vander Poorten, V.; Triantafyllou, A.; Thompson, L. D. R.; Bishop, J.; Hauben, E.; Hunt, J.; Skalova, A.; Stenman, G.; Takes, R. P.; Gnepp, D. R.; Hellquist, H.; Wenig, B.; Bell, D.; Rinaldo, A.; Ferlito, A. (2015). "Salivary acinic cell carcinoma: reappraisal and update". European Archives of Oto-Rhino-Laryngology. 273 (11): 3511–3531. doi:10.1007/s00405-015-3855-7. ISSN 0937-4477.

Template:WH Template:WS

[Vander_PoortenMarchal2010-1] Vander Poorten, Vincent L. M.; Marchal, Francis; Nuyts, Sandra; Clement, Paul M. J. (2010). "Parotid carcinoma: Current diagnostic workup and treatment". Indian Journal of Surgical Oncology. 1 (2): 96–111. doi:10.1007/s13193-010-0022-x. ISSN 0975-7651.

[PatelSanghvi2013-2] Patel, Neal R.; Sanghvi, Saurin; Khan, Mohemmed N.; Husain, Qasim; Baredes, Soly; Eloy, Jean Anderson (2013). "Demographic trends and disease‐specific survival in salivary acinic cell carcinoma: An analysis of 1129 cases". The Laryngoscope. 124 (1): 172–178. doi:10.1002/lary.24231. ISSN 0023-852X.

[BironLentsch2015-3] Biron, Vincent L.; Lentsch, Eric J.; Gerry, Daniel R.; Bewley, Arnaud F. (2015). "Factors influencing survival in acinic cell carcinoma: A retrospective survival analysis of 2061 patients". Head & Neck. 37 (6): 870–877. doi:10.1002/hed.23686. ISSN 1043-3074.

[Vander_PoortenTriantafyllou2015-4] Vander Poorten, V.; Triantafyllou, A.; Thompson, L. D. R.; Bishop, J.; Hauben, E.; Hunt, J.; Skalova, A.; Stenman, G.; Takes, R. P.; Gnepp, D. R.; Hellquist, H.; Wenig, B.; Bell, D.; Rinaldo, A.; Ferlito, A. (2015). "Salivary acinic cell carcinoma: reappraisal and update". European Archives of Oto-Rhino-Laryngology. 273 (11): 3511–3531. doi:10.1007/s00405-015-3855-7. ISSN 0937-4477.

[1]

[2]

[3]

[4]